Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinantsRoland J. Fuchs, Dieter K. Hossfeld, C. Nerl et al.|Leukemia|2017Cited by 339
Tolerability-Adapted Imatinib 800 mg/d Versus 400 mg/d Versus 400 mg/d Plus Interferon-α in Newly Diagnosed Chronic Myeloid LeukemiaRüdiger Hehlmann, Susanne Saußele, Michael Lauseker et al.|Journal of Clinical Oncology|2011Cited by 323
Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IVRüdiger Hehlmann, Andreas Hochhaus, Martin C. Müller et al.|Journal of Clinical Oncology|2013Cited by 299
Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemiaRüdiger Hehlmann, Aloïs Gratwohl, Ute Berger et al.|Blood|2007Cited by 168